
Nicotine E-Cigarette Cessation Trial
ORCA-V1 is a multi-center, double-blind, randomized, placebo-controlled, Phase 2 study being conducted in male or female adults who are daily nicotine e-cigarette users only, who intend to try to quit vaping and willing to set a quit date that is within 7-14 days from the start of cytisinicline treatment.
A total of approximately 150 subjects will be randomly assigned to one of two arms:
- Arm A, 12 weeks cytisinicline + behavior support: N=100
- Arm B, 12 weeks of placebo+ behavior support: N=50

ORCA-V1 Trial Locations
ORCA-V1 is being conducted at the following locations in the US.
d/b/a Massachusetts General Hospital
https://rally.partners.org/
617-726-7443
Alliance for Multispecialty Research
(Volunteer Research Group)
https://volresearch.com/
865-305-3784
Alliance for Multispecialty Research
(Central Kentucky Research)
https://www.amrlexington.com/
859-264-8999
Coastal Carolina Research
https://coastalcarolinaresearch.com/study-inquiry-form/
843-856-3784
Rochester Clinical Research
https://www.rcrclinical.com/
585-288-0890